Depemokimab (Exdensur) for Severe Eosinophilic Asthma
Abstract
The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala) and reslizumab (Cinqair) and the IL-5 receptor alpha antagonist benralizumab (Fasenra) were approved earlier.
Fields of Study & Subjects
Asthma and respiratory diseases
IL-33
ST2
and ILC Pathways
Allergic Rhinitis and Sensitization
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1750
- Pages
- 44–46
- Publication date
- 16 March 2026
- Language
- EN